To analyze national trends using the National Cancer Database (NCDB) in use of androgen deprivation therapy (ADT), outside of standard of care, in patients with very low risk prostate cancer.
We identified 52,797 men in the NCDB from 2010 to 2015 diagnosed with very low risk prostate cancer as defined (cT1cM0, PSA <10, Gleason ≤6, <3 biopsy cores positive). We evaluated the treatment trends and the proportion of men treated with ADT based on race, income, insurance status, treatment facility volume, and Charlson comorbidity.
From 2010 to 2015, prevalence of primary ADT use in patients with very low risk prostate cancer remained 0.7%. Patients treated at low-volume facilities were more likely to receive primary ADT (hazard ratio [HR] 1.29, P <.001) as were black patients (HR 1.47, P <.001). When evaluated over time, the proportion of men treated with primary ADT who were white decreased while the proportion of men who were black increased.
The use of primary ADT in men with very low risk prostate cancer has not changed over time, and may be over utilized, particularly among black men and those treated at low-volume facilities.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics, 2013.CA Cancer J Clin. 2013; 63: 11-30
National Comprehensive Cancer Network (NCNN).Clinical practice guidelines in oncology: prostate cancer. V.2.2018, 2018 (www.nccn.org).
- Mayo clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy.J Urol. 2008; 179: 1354-1361
- Do adenocarcinomas of the prostate with Gleason score (GS)<=6 have the potential to metastasize to lymph nodes?.Am J Surg Pathol. 2012; 36: 1346-1352
- 20 year prostate cancer specific mortality after radical prostatectomy.J Urol. 2011; 185: 869-875
- Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.J Clin Oncol. 2015; 33: 272-277
- The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.Ann Surg Oncol. 2008; 15: 683-690
- Survival following primary androgen deprivation therapy among men with localized prostate cancer.JAMA. 2008; 300: 173-181
- Critical evaluation of hormonal therapy for carcinoma of the prostate.Urology. 2002; 60: 201-208
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trail.Lancet. 2002; 360: 103-106
- 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trail.JAMA. 2004; 292: 821-827
- Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer.Urology. 2002; 60: 7-12
- National practice patterns and time trends in androgen ablation for localized prostate cancer.J Natl Cancer Inst. 2003; 95: 981-989
- Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma.Cancer. 2005; 103: 1615-1624
- Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer.Eur Urol. 2015; 68: 32-39
- Risk of clinical fractures after gonadotropin releasing hormone agonist therapy for prostate cancer.J Urol. 2006; 175: 136-139
- Excess mortality following hip fracture: a systematic epidemiological review.Osteoporos Int. 2009; 20: 1633-1650https://doi.org/10.1007/s00198-009-0920-3
- Androgen ablation for low-risk prostate cancer is common among male hip fracture patients.Scan J Urol. 2014; 48: 189-194
- Differences in clinical characteristics and disease free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.Cancer. 2006; 106: 789-795
- Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study.J Natl Cancer Inst. 2001; 93: 388-395
- Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States).Cancer Causes Control. 2006; 17: 803-811
- Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.J Natl Cancer Inst. 2003; 95: 1702-1710
- Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate.J Clin Oncol. 1995; 13: 93-100
- Geographic and socioeconomic variation in the treatment of prostate cancer.J Clin Oncol. 1995; 13: 93-100
- Radical prostatectomy: lower rates among African-American men.J Natl Med Assoc. 1996; 88: 589-594
- Trends and black/white differences in treatment for nonmetastatic prostate cancer.Med Care. 1998; 36: 1337-1348
- Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.J Natl Cancer Inst. 2001; 93: 1864-1871
Published online: April 29, 2019
Accepted: February 6, 2019
Received: December 7, 2018
© 2019 Published by Elsevier Inc.